- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00319228
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK segment (Segment I), the subjects would remain on their current anticoagulation therapy except for subjects on heparin therapy where a wash-out period of at least 5 half-lives would be required. In total, 15 subjects with congenital ATIII Deficiency will be enrolled for the PK assessment (Segment I).
For Segment II, fifteen episodes will be treated. Recruitment of individual subjects with high risk for venous thrombosis for Segment II of this study is necessary because of the rarity of Antithrombin deficiency in the population.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Congenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should be equal to or less than 60%.
- Age >12 years with a body weight of no less than 30 kg.
- Have not participated in another investigational study for at least 30 days. For Segment II, enrollment requires a pregnancy/delivery or a surgical procedure (it should be a major surgery although data from a minor surgery will also be collected).
- Documented personal history of major thromboembolic or thrombotic event.
- Male or female
- HIV, HBV, HCV, HAV and PARVO B19 status known prior to entry.
- The subject is willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
- The subject has signed an informed consent form (if at least 18 years old), or the subject's parent or legal guardian has signed the informed consent form. Subjects below the age of 18 years will also be asked to sign an assent form. All consent and assent forms must be approved in advance by the Institutional Review Board of the investigator's institution.
- Patients with heparin-associated thrombocytopenia who require anticoagulation with non-heparin containing drugs will be eligible if they can be safely transitioned during the washout period for the Segment I PK study.
- If pregnant, a woman must be Parvo B19 IgG antibody positive.
Exclusion Criteria:
- Acquired deficiency of ATIII.
- Receiving concomitant treatment for thrombophilic disorders other than ATIII deficiency.
- Inability or unwillingness to comply with the protocol requirements.
- History of anaphylactic reaction(s) to blood or blood components.
- Allergies to excipients.
- Liver function tests >/= 2.5 X ULN
- Serum creatinine >1.2 X ULN.
- Urine >/= 2+ protein with urine dipstick test.
- The subject is known to have abused alcohol or illicit drugs within the past 12 months.
- The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative or unable to provide a storage serum sample at the screening visit.
- Patients on heparin-treatment who, for clinical reasons, cannot safely be discontinued from heparin therapy during the PK segment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antithrombin III
|
Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient. Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objectives of this clinical study are to:
Time Frame: 2 years
|
2 years
|
Assess the pharmacokinetic (PK) profile of AT-III in congenital AT-III deficient patients
Time Frame: 1 year
|
1 year
|
To measure the in vivo recovery and half-life of AT-III.
Time Frame: 1 year
|
1 year
|
To assess the clinical safety and tolerability of AT-III-DAF/DI.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess clinical efficacy by preventing thromboembolic or thrombotic events (prophylaxis) in individuals with congenital AT-III deficiency who are undergoing surgical procedures or who are pregnant and undergoing parturition.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paul Pinciaro, PhD, Grifols Biologicals, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IG-401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antithrombin III Deficiency
-
OctapharmaNot yet recruiting
-
OctapharmaRecruitingCongenital Antithrombin DeficiencySpain, Italy, United States, Serbia, France, Hungary, Austria, Germany, United Kingdom, Israel
-
Kyowa Hakko Kirin UK, Ltd.CompletedCongenital Antithrombin DeficiencyFrance, Germany, Italy, Sweden, United Kingdom
-
Mayo ClinicrEVO BiologicsWithdrawnAntithrombin Deficiency Type 2
-
University Health Network, TorontoQueen's UniversityNot yet recruitingAntithrombin III Levels | Albumin LevelsCanada
-
Instituto Grifols, S.A.CompletedCoronary Artery Bypass | Acquired Antithrombin III DeficiencyItaly
-
Mayo ClinicrEVO BiologicsTerminatedThrombophilia Due to Acquired Antithrombin III DeficiencyUnited States
-
rEVO BiologicsCompletedAntithrombin Deficiency, CongenitalFrance, United Kingdom, Germany, United States, Sweden, Italy
-
Rennes University HospitalCompletedSevere Cardiac InsufficiencyFrance
-
Duke UniversityGrifols Biologicals, LLCCompletedATIII DeficiencyUnited States
Clinical Trials on Plasma-derived AT-III concentrate
-
Grifols Therapeutics LLCInstituto Grifols, S.A.CompletedCongenital AfibrinogenemiaIndia, United States, Italy, Lebanon
-
OctapharmaCompletedCongenital Fibrinogen Deficiency | AfibrinogenemiaIran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
-
Grifols Therapeutics LLCInstituto Grifols, S.A.Recruiting
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Sintesi Research SrlUnknown
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseUnited States, Germany, United Kingdom, Italy, Austria, Canada
-
BiotestAccovion GmbH; ICON plc; SYNLAB Analytics and Services Germany GmbH; Phoenix Clinical... and other collaboratorsCompletedCongenital Afibrinogenemia | Congenital HypofibrinogenemiaBulgaria, Egypt, Germany, Lebanon, Tunisia
-
Kaohsiung Medical University Chung-Ho Memorial...Ministry of Health and Welfare, TaiwanCompletedAnterior Cruciate Ligament ReconstructionTaiwan
-
University of L'AquilaTRIB s.r.l.Completed
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterFoundation for Physical Medicine and RehabilitationCompletedKnee OsteoarthritisUnited States
-
Institute of Liver and Biliary Sciences, IndiaCompleted